Quarterly report · Q3
2796.TEDINET S100QKFA
Period2022-06-01 → 2023-02-28
Filed2023-04-07
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 36
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥38.7bn | 2022-06-01 → 2023-02-28 | Cons. | Net sales |
| Revenue | ¥51.6bn | 2021-06-01 → 2022-05-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥38.6bn | 2021-06-01 → 2022-02-28 | Cons. | Net sales |
| Operating income | ¥896m | 2022-06-01 → 2023-02-28 | Cons. | Operating income |
| Operating income | ¥1.0bn | 2021-06-01 → 2022-02-28 | Cons. | Operating income |
| Ordinary income | ¥890m | 2022-06-01 → 2023-02-28 | Cons. | Ordinary income |
| Ordinary income | ¥1.5bn | 2021-06-01 → 2022-05-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.0bn | 2021-06-01 → 2022-02-28 | Cons. | Ordinary income |
| Profit before tax | ¥722m | 2022-06-01 → 2023-02-28 | Cons. | Income before income taxes |
| Profit before tax | ¥967m | 2021-06-01 → 2022-02-28 | Cons. | Income before income taxes |
| Net income (owners) | ¥208m | 2022-06-01 → 2023-02-28 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥447m | 2021-06-01 → 2022-05-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥322m | 2021-06-01 → 2022-02-28 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥218m | 2022-06-01 → 2023-02-28 | Cons. | Profit loss |
| Net income | ¥326m | 2021-06-01 → 2022-02-28 | Cons. | Profit loss |
| Total assets | ¥22.9bn | at 2023-02-28 | Cons. | Assets |
| Total assets | ¥23.7bn | at 2022-05-31 | Cons. | Assets |
| Total assets | ¥23.8bn | at 2022-02-28 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥16.1bn | at 2023-02-28 | Cons. | Liabilities |
| Total liabilities | ¥17.0bn | at 2022-05-31 | Cons. | Liabilities |
| Net assets / equity | ¥6.8bn | at 2023-02-28 | Cons. | Net assets |
| Net assets / equity | ¥6.7bn | at 2022-05-31 | Cons. | Net assets |
| Net assets / equity | ¥6.6bn | at 2022-02-28 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥4.4bn | at 2023-02-28 | Cons. | Cash and deposits |
| Cash and deposits | ¥4.0bn | at 2022-05-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥22.24 | 2022-06-01 → 2023-02-28 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥14.45 | 2022-12-01 → 2023-02-28d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥47.99 | 2021-06-01 → 2022-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥34.6 | 2021-06-01 → 2022-02-28 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥7.68 | 2021-12-01 → 2022-02-28d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥16.89 | 2022-06-01 → 2023-02-28 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥36.29 | 2021-06-01 → 2022-05-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥26.16 | 2021-06-01 → 2022-02-28 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 28.4% | at 2023-02-28 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 26.9% | at 2022-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 26.4% | at 2022-02-28 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 44
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-06-01 → 2023-02-28 | ¥573m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-06-01 → 2023-02-28 | ¥573m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-06-01 → 2023-02-28 | ¥37m |
| Reconciling Itemsreconciling | segment profit | 2022-06-01 → 2023-02-28 | −¥226m |
| jpcrp040300-q3r_E05379-000Cosmetic Drug And Convenience Storereportable segment | revenue | 2022-06-01 → 2023-02-28 | ¥5.8bn |
| jpcrp040300-q3r_E05379-000Cosmetic Drug And Convenience Storereportable segment | revenue external | 2022-06-01 → 2023-02-28 | ¥5.8bn |
| jpcrp040300-q3r_E05379-000Cosmetic Drug And Convenience Storereportable segment | segment profit | 2022-06-01 → 2023-02-28 | −¥170m |
| jpcrp040300-q3r_E05379-000Custody Of Medical Documentsreportable segment | revenue | 2022-06-01 → 2023-02-28 | ¥485m |
| jpcrp040300-q3r_E05379-000Custody Of Medical Documentsreportable segment | revenue external | 2022-06-01 → 2023-02-28 | ¥485m |
| jpcrp040300-q3r_E05379-000Custody Of Medical Documentsreportable segment | segment profit | 2022-06-01 → 2023-02-28 | ¥56m |
| jpcrp040300-q3r_E05379-000Dispensing Pharmacyreportable segment | revenue | 2022-06-01 → 2023-02-28 | ¥31.5bn |
| jpcrp040300-q3r_E05379-000Dispensing Pharmacyreportable segment | revenue external | 2022-06-01 → 2023-02-28 | ¥31.5bn |
| jpcrp040300-q3r_E05379-000Dispensing Pharmacyreportable segment | segment profit | 2022-06-01 → 2023-02-28 | ¥1.1bn |
| jpcrp040300-q3r_E05379-000Medical Mallreportable segment | revenue | 2022-06-01 → 2023-02-28 | ¥378m |
| jpcrp040300-q3r_E05379-000Medical Mallreportable segment | revenue external | 2022-06-01 → 2023-02-28 | ¥378m |
| jpcrp040300-q3r_E05379-000Medical Mallreportable segment | segment profit | 2022-06-01 → 2023-02-28 | ¥70m |
| —segment total | revenue | 2022-06-01 → 2023-02-28 | ¥38.2bn |
| —segment total | revenue external | 2022-06-01 → 2023-02-28 | ¥38.2bn |
| —segment total | segment profit | 2022-06-01 → 2023-02-28 | ¥1.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-06-01 → 2023-02-28 | ¥38.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-06-01 → 2023-02-28 | ¥38.7bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-06-01 → 2023-02-28 | ¥1.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-06-01 → 2022-02-28 | ¥560m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-06-01 → 2022-02-28 | ¥560m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-06-01 → 2022-02-28 | ¥22m |
| Reconciling Itemsreconciling | segment profit | 2021-06-01 → 2022-02-28 | −¥235m |
| jpcrp040300-q3r_E05379-000Cosmetic Drug And Convenience Storereportable segment | revenue | 2021-06-01 → 2022-02-28 | ¥5.7bn |
| jpcrp040300-q3r_E05379-000Cosmetic Drug And Convenience Storereportable segment | revenue external | 2021-06-01 → 2022-02-28 | ¥5.7bn |
| jpcrp040300-q3r_E05379-000Cosmetic Drug And Convenience Storereportable segment | segment profit | 2021-06-01 → 2022-02-28 | −¥151m |
| jpcrp040300-q3r_E05379-000Custody Of Medical Documentsreportable segment | revenue | 2021-06-01 → 2022-02-28 | ¥516m |
| jpcrp040300-q3r_E05379-000Custody Of Medical Documentsreportable segment | revenue external | 2021-06-01 → 2022-02-28 | ¥516m |
| jpcrp040300-q3r_E05379-000Custody Of Medical Documentsreportable segment | segment profit | 2021-06-01 → 2022-02-28 | ¥71m |
| jpcrp040300-q3r_E05379-000Dispensing Pharmacyreportable segment | revenue | 2021-06-01 → 2022-02-28 | ¥31.4bn |
| jpcrp040300-q3r_E05379-000Dispensing Pharmacyreportable segment | revenue external | 2021-06-01 → 2022-02-28 | ¥31.4bn |
| jpcrp040300-q3r_E05379-000Dispensing Pharmacyreportable segment | segment profit | 2021-06-01 → 2022-02-28 | ¥1.2bn |
| jpcrp040300-q3r_E05379-000Medical Mallreportable segment | revenue | 2021-06-01 → 2022-02-28 | ¥377m |
| jpcrp040300-q3r_E05379-000Medical Mallreportable segment | revenue external | 2021-06-01 → 2022-02-28 | ¥377m |
| jpcrp040300-q3r_E05379-000Medical Mallreportable segment | segment profit | 2021-06-01 → 2022-02-28 | ¥48m |
| —segment total | revenue | 2021-06-01 → 2022-02-28 | ¥38.0bn |
| —segment total | revenue external | 2021-06-01 → 2022-02-28 | ¥38.0bn |
| —segment total | segment profit | 2021-06-01 → 2022-02-28 | ¥1.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-06-01 → 2022-02-28 | ¥38.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-06-01 → 2022-02-28 | ¥38.6bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-06-01 → 2022-02-28 | ¥1.2bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 387
| Item | Context | Value | Unit |
|---|---|---|---|
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の４の７第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2023-04-07 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第37期第３四半期(自 令和４年12月１日 至 令和５年２月28日) | |
| Company name cover page | FilingDateInstant | Original text (Japanese)ファーマライズホールディングス株式会社 | |
| Company name in english cover page | FilingDateInstant | Ｐｈａｒｍａｒｉｓｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役 社長 秋 山 昌 之 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都中野区中央一丁目38番１号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)03-3362-7130（代表） | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)取締役 沼 田 豊 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都中野区中央一丁目38番１号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | Original text (Japanese)03-3362-7130（代表） | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)取締役 沼 田 豊 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E05379 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 27960 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)ファーマライズホールディングス株式会社 | |
| Filer name in english | FilingDateInstant | Pharmarise Holdings Corporation | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | cte | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Current fiscal year start date | FilingDateInstant | 2022-06-01 | |
| Current period end date | FilingDateInstant | 2023-02-28 | |
| Type of current period | FilingDateInstant | Q3 | |
| Current fiscal year end date | FilingDateInstant | 2023-05-31 | |
| Previous fiscal year start date | FilingDateInstant | 2021-06-01 | |
| Comparative period end date | FilingDateInstant | 2022-02-28 | |
| Previous fiscal year end date | FilingDateInstant | 2022-05-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Business risks (text) | FilingDateInstant | Text · Plus | |
| Management analysis of financial position operating results and cash flows (text) | FilingDateInstant | Text · Plus | |
| Critical contracts for operation (text) | FilingDateInstant | Text · Plus | |
| Total number of shares (text) | FilingDateInstant | Text · Plus | |
| Issued shares total number of shares etc (text) | FilingDateInstant | Text · Plus | |
| Class issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)普通株式 | |
| Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registered | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)東京証券取引所 プライム市場 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |